001     292095
005     20241118124022.0
024 7 _ |a 10.1038/s41467-024-50932-7
|2 doi
024 7 _ |a pmid:39103364
|2 pmid
024 7 _ |a altmetric:166027397
|2 altmetric
037 _ _ |a DKFZ-2024-01594
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Went, Molly
|0 0000-0003-3271-975X
|b 0
245 _ _ |a Deciphering the genetics and mechanisms of predisposition to multiple myeloma.
260 _ _ |a [London]
|c 2024
|b Nature Publishing Group UK
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723018807_13786
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Multiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel. Through functional fine-mapping and Mendelian randomization, we uncover two causal mechanisms for inherited MM risk: longer telomeres; and elevated levels of B-cell maturation antigen (BCMA) and interleukin-5 receptor alpha (IL5RA) in plasma. The largest increase in BCMA and IL5RA levels is mediated by the risk variant rs34562254-A at TNFRSF13B. While individuals with loss-of-function variants in TNFRSF13B develop B-cell immunodeficiency, rs34562254-A exerts a gain-of-function effect, increasing MM risk through amplified B-cell responses. Our results represent an analysis of genetic MM predisposition, highlighting causal mechanisms contributing to MM development.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a B-Cell Maturation Antigen
|2 NLM Chemicals
650 _ 7 |a TNFRSF13B protein, human
|2 NLM Chemicals
650 _ 7 |a Transmembrane Activator and CAML Interactor Protein
|2 NLM Chemicals
650 _ 2 |a Multiple Myeloma: genetics
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Genetic Predisposition to Disease
|2 MeSH
650 _ 2 |a Genome-Wide Association Study
|2 MeSH
650 _ 2 |a B-Cell Maturation Antigen: genetics
|2 MeSH
650 _ 2 |a Polymorphism, Single Nucleotide
|2 MeSH
650 _ 2 |a Mendelian Randomization Analysis
|2 MeSH
650 _ 2 |a B-Lymphocytes: immunology
|2 MeSH
650 _ 2 |a B-Lymphocytes: metabolism
|2 MeSH
650 _ 2 |a Case-Control Studies
|2 MeSH
650 _ 2 |a Transmembrane Activator and CAML Interactor Protein: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Telomere: genetics
|2 MeSH
700 1 _ |a Duran-Lozano, Laura
|b 1
700 1 _ |a Halldorsson, Gisli H
|0 0000-0001-7067-9862
|b 2
700 1 _ |a Gunnell, Andrea
|0 0000-0001-5162-5391
|b 3
700 1 _ |a Ugidos-Damboriena, Nerea
|b 4
700 1 _ |a Law, Philip
|0 0000-0001-9663-4611
|b 5
700 1 _ |a Ekdahl, Ludvig
|b 6
700 1 _ |a Sud, Amit
|0 0000-0002-6133-0164
|b 7
700 1 _ |a Thorleifsson, Gudmar
|0 0000-0003-4623-9087
|b 8
700 1 _ |a Thodberg, Malte
|0 0000-0001-6244-3841
|b 9
700 1 _ |a Olafsdottir, Thorunn
|0 0000-0001-5454-938X
|b 10
700 1 _ |a Lamarca-Arrizabalaga, Antton
|0 0009-0008-3426-2347
|b 11
700 1 _ |a Cafaro, Caterina
|b 12
700 1 _ |a Niroula, Abhishek
|0 0000-0002-5904-0635
|b 13
700 1 _ |a Ajore, Ram
|b 14
700 1 _ |a Lopez de Lapuente Portilla, Aitzkoa
|b 15
700 1 _ |a Ali, Zain
|b 16
700 1 _ |a Pertesi, Maroulio
|0 0000-0002-4869-8925
|b 17
700 1 _ |a Goldschmidt, Hartmut
|b 18
700 1 _ |a Stefansdottir, Lilja
|b 19
700 1 _ |a Kristinsson, Sigurdur Y
|b 20
700 1 _ |a Stacey, Simon N
|0 0000-0002-4732-7380
|b 21
700 1 _ |a Love, Thorvardur J
|b 22
700 1 _ |a Rognvaldsson, Saemundur
|b 23
700 1 _ |a Hajek, Roman
|0 0000-0001-6955-6267
|b 24
700 1 _ |a Vodicka, Pavel
|b 25
700 1 _ |a Pettersson-Kymmer, Ulrika
|0 0000-0002-0557-9803
|b 26
700 1 _ |a Späth, Florentin
|b 27
700 1 _ |a Schinke, Carolina
|0 0000-0002-2699-1741
|b 28
700 1 _ |a Van Rhee, Frits
|0 0000-0001-9959-1282
|b 29
700 1 _ |a Sulem, Patrick
|0 0000-0001-7123-6123
|b 30
700 1 _ |a Ferkingstad, Egil
|0 0000-0001-8090-7988
|b 31
700 1 _ |a Hjorleifsson Eldjarn, Grimur
|0 0000-0002-9580-6685
|b 32
700 1 _ |a Mellqvist, Ulf-Henrik
|b 33
700 1 _ |a Jonsdottir, Ingileif
|0 0000-0001-8339-150X
|b 34
700 1 _ |a Morgan, Gareth
|0 0000-0002-4271-6360
|b 35
700 1 _ |a Sonneveld, Pieter
|b 36
700 1 _ |a Waage, Anders
|0 0000-0001-9072-1220
|b 37
700 1 _ |a Weinhold, Niels
|0 P:(DE-He78)66b39a79f3f922997656d7b902d324fb
|b 38
|u dkfz
700 1 _ |a Thomsen, Hauke
|b 39
700 1 _ |a Försti, Asta
|0 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
|b 40
|u dkfz
700 1 _ |a Hansson, Markus
|0 0000-0002-7715-4548
|b 41
700 1 _ |a Juul-Vangsted, Annette
|0 0000-0002-2131-731X
|b 42
700 1 _ |a Thorsteinsdottir, Unnur
|b 43
700 1 _ |a Hemminki, Kari
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 44
|u dkfz
700 1 _ |a Kaiser, Martin
|0 0000-0002-3677-4804
|b 45
700 1 _ |a Rafnar, Thorunn
|0 0000-0003-0491-7046
|b 46
700 1 _ |a Stefansson, Kari
|0 0000-0003-1676-864X
|b 47
700 1 _ |a Houlston, Richard
|0 0000-0002-5268-0242
|b 48
700 1 _ |a Nilsson, Björn
|0 0000-0001-5542-0254
|b 49
773 _ _ |a 10.1038/s41467-024-50932-7
|g Vol. 15, no. 1, p. 6644
|0 PERI:(DE-600)2553671-0
|n 1
|p 6644
|t Nature Communications
|v 15
|y 2024
|x 2041-1723
856 4 _ |u https://inrepo02.dkfz.de/record/292095/files/s41467-024-50932-7.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/292095/files/s41467-024-50932-7.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:292095
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 38
|6 P:(DE-He78)66b39a79f3f922997656d7b902d324fb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 40
|6 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 44
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT COMMUN : 2022
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:09:09Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:09:09Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2023-05-02T09:09:09Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-05-02T09:09:09Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-08-29
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NAT COMMUN : 2022
|d 2023-08-29
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-29
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-29
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)Z999-20160331
|k Z999
|l Erimitus im DKFZ
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)Z999-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21